Clinical Trials Logo

Severe Infection clinical trials

View clinical trials related to Severe Infection.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06260345 Recruiting - Severe Infection Clinical Trials

CommunautAry Pediatric bacteRial Infection in Intensive CarE Unit

CAPRICE
Start date: January 1, 2024
Phase:
Study type: Observational

Severe bacterial infections are a worldwide scourge. However, the epidemiology of this type of infection varies over time. It is therefore essential to monitor them in order to prevent them more effectively. At this time, in France, no monitoring exists for this kind of infections.

NCT ID: NCT06185920 Recruiting - Severe Infection Clinical Trials

PHAGEinLYON Clinic Cohort Study: a Descriptive Study of Severe Infections Treated With Phage Therapy at the HCL.

Start date: February 1, 2023
Phase:
Study type: Observational

PHAGEinLYON Clinic cohort study is a single site non-interventional retrospective and prospective study, initiated by the Hospices Civils de Lyon. Population targeted are patients with a severe infection treated with bacteriophage in the Hospices civils de Lyon from 2015 to 2033. The primary objective is to describe the severe infections treated with phagotherapy. 250 patients will be included in the study.

NCT ID: NCT06161870 Recruiting - Severe Infection Clinical Trials

Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model

Start date: January 1, 2021
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to compare the clinical efficacy of individualized dosing based on the population pharmacokinetics (PK) model and empirical dosing of vancomycin in participants with severe infections. It aims to answer whether individual vancomycin dosing based on population PK model is superior to empirical dosing in terms of clinical efficacy and safety. Participants will be randomly divided into experimental group and control group. The experimental group will be guided by the population PK model for individual dosing, and the control group will be given empirical dosing. Demographic data, clinical characteristics of participants, and their trough concentrations (Cmin) and peak concentrations (Cmax) of vancomycin will be collected. Area under the concentration curve (AUC24) of participants will be calculated using the first-order PK equation. Researchers will compare experimental group and control group to see if individual vancomycin dosing based on population PK model is superior to empirical dosing in terms of clinical efficacy and safety.

NCT ID: NCT05788861 Recruiting - Risk Factors Clinical Trials

Invasive Group A Streptococcal Infection

ISAI
Start date: September 1, 2022
Phase:
Study type: Observational

This study is observational, retrospective and prospective study in pediatric patients hospitalized with invasive streptococcal A infection

NCT ID: NCT05602324 Recruiting - Severe Infection Clinical Trials

Nutritional Supplement for Patients With Severe Infection

NUWISE
Start date: October 1, 2021
Phase: N/A
Study type: Interventional

This is a randomized trial testing a supplement that has been approved by Health Canada to support healthy cholesterol levels (i.e. high density lipoprotein (HDL) cholesterol). This trial is proposing to use this approved supplement to determine whether it is able to raise HDL cholesterol in patients treated in the intensive care unit (ICU) with severe infection who have detrimentally low levels of HDL cholesterol. Patients who present to the ICU with severe infection will be approached for consent. If they choose to participate, patients will be given usual care or a 150mL daily nutritional supplement containing lauric acid (15 ml) and Berberine (1000 mg) daily for 14 days. Participants will be followed during their stay in the ICU and will receive follow up phone calls at Day 28 and 90.

NCT ID: NCT04990908 Recruiting - Severe Infection Clinical Trials

Systematic Screening for Primary Immunodeficiencies in Patients Admitted for Severe Infection in Pediatric Intensive Care Unit

SPYSI
Start date: September 4, 2023
Phase:
Study type: Observational

Severe infections in pediatric intensive care unit are not uncommon. Historically, the diagnosis of hereditary (primary) immune deficiency required a combination of recurrent clinical signs and biological stigmas. This paradigm is currently being questioned, and grows the hypothesis of a potential underlying genetic susceptibility in any severe infection. To date, the proportion of severe infections explained by an underlying immune deficiency is unknown. The aim of this prospective study is to assess the incidence of primary immune deficiencies in children with severe infection, regardless of their etiology.

NCT ID: NCT04923828 Recruiting - Severe Infection Clinical Trials

Chinese PICU Collaborative Network on Pathogens and Drug Resistance of Severe Infections

Start date: December 31, 2023
Phase:
Study type: Observational [Patient Registry]

To investigate PICUs in major cities in China by establishing a high-quality standardized clinical database of PICU inpatients Incidence, fatality rate, pathogen distribution, anti-infective treatment of community-acquired/nosocomial infections in inpatients.

NCT ID: NCT04650607 Recruiting - Clinical trials for Prosthetic Joint Infection

Phage Safety Cohort Study

PHA-SA-CO
Start date: May 9, 2022
Phase:
Study type: Observational

This cohort study aims to describe the adverse events related to the use of bacteriophages to treat serious infections, data from the literature being almost non-existent on this subject.

NCT ID: NCT02167802 Recruiting - Severe Infection Clinical Trials

Construction and Validation of a Tool for Automatic Identification of Care Pathways at Risk of Sub-optimality in the Management of Severe Infections in Children (DIABACT IV)

DIABACT IV
Start date: March 20, 2015
Phase:
Study type: Observational

Community bacterial infection remains to this day a common cause of morbidity and mortality in children, which preventability is a challenge for clinicians. In a previous work, the investigators found that 76% supported children admitted to the ICU for severe bacterial infection were appraised as suboptimal and significantly associated with an increased risk of death. In this context, the investigators seek to identify indicators of extractable data PMSI and SNIIR -AM associated with a higher risk of suboptimal early taking care of children with severe bacterial infection in order to combine them and use them as a score or decision tree that the investigators will validate data from a national prospective multicenter study including 512 children admitted to the ICU for severe infection. The investigators then propose a score associated with a risk of suboptimality care to evaluate the performance of the healthcare system .